Business Wire News Releases | Owen Sound Sun Times
Bluma Wellness Announces Proposed Warrant Repricing and Redemption of Debentures
TORONTO — Bluma Wellness Inc. (the “ Company ”) (CSE: BWEL.U) (OTCQX:BMWLF) announces today that it proposes to amend the exercise price of up to 45,869,475 common share purchase warrants of the Company (collectively, the “ Warrants ”) to a price of US$1.01 per common share in the capital of the Company (each a “ Common Share ”), representing the closing price of the Common Shares on the Canadian Securities Exchange (the “ CSE ”) on January 14, 2021 (the “ Repricing ”). The Warrants were issued on various dates between June 26, 2020 and October 30, 2020, in connection with the conversion of the outstanding principal and accrued interest on the then issued and outstanding 12.5% unsecured convertible debentures of the Company (“ 12.5% Debentures ”) in accordance with their terms. The Warrants are currently exercisable for a period of two years from the date of issuance into Common Shares at an exercise price per Common Share currently equal to the greater of: (i) US$1.00; (ii) the volume weighted average price at which the Common Shares have traded on the CSE during the five trading days ending on the date of exercise; and (iii) 110% of the price at which the 12.5% Debentures were converted. No other terms of the Warrants will be amended other than for fixing their exercise price at US$1.01. Completion of the Repricing is subject to approval of the CSE and the unanimous approval of the holders of the Warrants.
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 VANCOUVER, British Columbia — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.
Versant Ventures Files Early Warning Report in Respect of Repare Therapeutics Inc.
VANCOUVER, British Columbia & MONTREAL — Versant Ventures today announced the filing of an early warning report with respect to the ownership of securities in Repare Therapeutics Inc. (the “Company”) by Versant Venture Capital VI, L.P., Versant Vantage I, L.P., Versant Venture Capital V, L.P., Versant Venture Capital V (Canada) LP, Versant Ophthalmic Affiliates Fund I, L.P. and Versant Affiliates Fund V, L.P. (collectively, the “Versant Funds”).
Columbia Care Receives Provisional License for Adult Use at its Patriot Care Dispensary in Downtown Boston
NEW YORK — Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) announced today it was awarded a provisional license from the Massachusetts Cannabis Control Commission for adult use retail sales at its medical marijuana dispensary, operated under Patriot Care, at 21 Milk Street in downtown Boston. In December, the Boston Zoning Board of Appeal approved a zoning permit that allows Patriot Care to expand its existing dispensary to include a co-located adult-use dispensary.
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
Publication of results from Phase 4 single-arm, open-label study in 91 healthy adults, age 20-40 years, to confirm reference standard for vaccine release to Israeli market Seroprotection at month 3 (after 2 doses) was 98.8%, increasing to 100% at month 7 (after 3 doses) GMC of anti-HBs titers was 413.6 mIU/mL and 6799.9 mIU/mL at month 3 and month 7, respectively Consistent with the known safety profile of VBI’s vaccine, no safety signals were observed CAMBRIDGE, Mass. — VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBI’s prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier. The study was designed to evaluate the immunogenicity of VBI’s 3-antigen HBV vaccine in support of the qualification of that batch as a new reference standard for vaccine release to the Israeli market, where VBI’s vaccine is available as Sci-B-Vac®.
Imperial to hold 2020 Fourth Quarter Earnings Call
CALGARY, Alberta — (TSE:IMO, NYSE American: IMO) Brad Corson, chairman, president and chief executive officer, and Dave Hughes, vice-president investor relations, Imperial Oil Limited, will host a 2020 Fourth Quarter Earnings Call on Tuesday, February 2, following the company’s fourth quarter earnings release that morning. The event begins at 9 a.m. MT and will be accessible by webcast.
weather (Owen Sound)
Nextech AR Signs Poly Deal
VANCOUVER, British Columbia — Nextech AR Solutions (Nextech) (OTCQB: NEXCF) (NEO: NTAR) (FSE: N29), a leading provider of augmented reality (AR) and virtual experience technologies (VXT) and services for 3D ads, eCommerce, education, conferences and events has signed a renewal agreement with Poly (NYSE: PLT), with an initial value of $470,000 for a six month term and the potential for additional revenue after the six months.
H.I.G. Realty Invests in Production Studios & Content Hub in Madrid
LONDON — H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies.
Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities
LUXEMBOURG — Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus.
Personas Sales Increase 63% Between Q4 2020 Compared to Q4 2019
TORONTO — Personas Social Incorporated (TSX.V: PRSN) (the “ Company ” or “ Personas ”) is pleased to provide a corporate update on annual sales increases on the Peeks Platform, which is one of the key revenue driving platforms that Personas offers in the social media and communications markets.
Slate Grocery REIT Announces Closing of US$169 Million Mortgage Loan
TORONTO — Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has closed a US$169 million mortgage loan with a 2031 maturity. The net proceeds from the loan are being used to reduce the REIT’s nearest term debt maturity in 2023 to US$83 million or 11% of total debt.
Starlight Hybrid Global Real Assets Trust Announces 2021 Cash Distributions
TORONTO — Starlight Investments Capital LP (“ Starlight Capital ”), on behalf of Starlight Hybrid Global Real Assets Trust (the “ Trust ”), announced today the 2021 monthly distributions for the Trust. Unitholders of record will receive cash “per-unit” distributions as per the below schedule:
Algoma Central Corporation Announces 31% Increase in Quarterly Dividend
ST. CATHARINES, Ontario — Algoma Central Corporation (“Algoma” or “the Company”) (TSX: ALC), a leading provider of marine transportation services, today announced that the Company’s Board of Directors authorized payment of a quarterly dividend to shareholders of $0.17 per common share.